[{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"Adenosine A2A receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Adial Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adial Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"1","companyTruncated":"Adial Pharmaceuticals \/ University of California"},{"orgOrder":0,"company":"Alvogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alvogen \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alvogen \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Bausch Health","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Bausch Health"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedars-Sinai \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Cedars-Sinai \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integra LifeSciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Integra LifeSciences \/ Undisclosed"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Vizera d.o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Archer Daniels Midland \/ Vizera d.o.o.","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Vizera d.o.o."},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Archer Daniels Midland \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Analyze & Realize"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Archer Daniels Midland \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Analyze & Realize"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Atlantia Food Clinical Trials | Vedic Lifesciences Pvt. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Archer Daniels Midland \/ Atlantia Food Clinical Trials | Vedic Lifesciences Pvt. Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Atlantia Food Clinical Trials | Vedic Lifesciences Pvt. Ltd."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Winclove Bio Industries BV","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Winclove Bio Industries BV","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ Winclove Bio Industries BV"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Kennesaw State University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Bacillus Subtilis DE111","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Archer Daniels Midland \/ Kennesaw State University","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Kennesaw State University"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Kennesaw State University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Digestive Enzyme Blend","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Archer Daniels Midland \/ Kennesaw State University","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Kennesaw State University"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Ensure Surgery Immunonutrition","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"University of North Texas, Denton, TX","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Enzyme Cocktail A","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Archer Daniels Midland \/ University of North Texas, Denton, TX","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ University of North Texas, Denton, TX"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"EB Medical Research | Quartesian","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"G3P-01","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQ Innovation \/ EB Medical Research | Quartesian","highestDevelopmentStatusID":"1","companyTruncated":"SQ Innovation \/ EB Medical Research | Quartesian"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Gluten","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Huo Ma Ren Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Undisclosed"},{"orgOrder":0,"company":"Infinant Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INF108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Infinant Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinant Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Infinant Health \/ Undisclosed"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Kratom Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gum, Chewing","sponsorNew":"Tauriga Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tauriga Sciences \/ Undisclosed"},{"orgOrder":0,"company":"METAGENICS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Multivitamin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"METAGENICS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"METAGENICS \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"METAGENICS \/ Undisclosed"},{"orgOrder":0,"company":"Seed Health","sponsor":"Curebase Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"PDS-08","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Seed Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seed Health \/ Curebase Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Seed Health \/ Curebase Inc."},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | National Center for Research Resources | Advanced Breath Diagnostics, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Spirulina","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ National Institute of Diabetes and Digestive and Kidney Diseases | National Center for Research Resources | Advanced Breath Diagnostics, LLC","highestDevelopmentStatusID":"1","companyTruncated":"Mayo Clinic \/ National Institute of Diabetes and Digestive and Kidney Diseases | National Center for Research Resources | Advanced Breath Diagnostics, LLC"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Vasculera","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primus Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Primus Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Avexegen Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Avexegen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avexegen Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Avexegen Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Gary E. Stein","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tigecycline","moa":"Bacterial 70S ribosome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Gary E. Stein","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Gary E. Stein"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Mohamed Saad","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pantoprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Mohamed Saad","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Mohamed Saad"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Details : Multivitamin is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Irritable Bowel Syndrome.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          August 19, 2025

                          Lead Product(s) : Multivitamin

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Details : Huo Ma Ren Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Constipation.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          July 29, 2025

                          Lead Product(s) : Huo Ma Ren Extract

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Details : Enzyme Cocktail A is a Enzyme drug candidate, which is currently being evaluated in clinical studies for the treatment of Digestive System Diseases.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          November 29, 2024

                          Lead Product(s) : Enzyme Cocktail A

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : University of North Texas, Denton, TX

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Details : Infinant Health's patented drug candidate is a Bifidobacterium longum subspecies infantis strain, INF108, being developed for the prevention of necrotizing enterocolitis in pre-term infants.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 02, 2024

                          Lead Product(s) : INF108

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Details : Ensure Surgery Immunonutrition is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Inflammatory Bowel Diseases.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          March 13, 2024

                          Lead Product(s) : Ensure Surgery Immunonutrition

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Details : This is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Constipation.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          October 16, 2023

                          Lead Product(s) : Probiotic

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Analyze & Realize

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Details : This is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Diarrhea.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          May 06, 2023

                          Lead Product(s) : Probiotic

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Analyze & Realize

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Details : This is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Irritable Bowel Syndrome.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          March 03, 2023

                          Lead Product(s) : Probiotic

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Vizera d.o.o.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Details : XIFAXAN (rifaximin) is a 2 week prescription treatment that provided up to 6 months of relief from IBS-D symptoms of abdominal pain and diarrhea in a clinical trial.

                          Product Name : Xifaxan-Generic

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          August 11, 2022

                          Lead Product(s) : Rifaximin

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Lead Product(s) : Probiotic

                          Therapeutic Area : Gastroenterology

                          Study Phase : Undisclosed

                          Sponsor : Atlantia Food Clinical Trials | Vedic Lifesciences Pvt. Ltd.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : This is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Colic.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          June 27, 2022

                          Lead Product(s) : Probiotic

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Atlantia Food Clinical Trials | Vedic Lifesciences Pvt. Ltd.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank